Ritchlin C
Semin Immunopathol. 2021; 43(2):279-290.
PMID: 33721040
DOI: 10.1007/s00281-021-00848-x.
Ogdie A, Coates L, Mease P
Arthritis Care Res (Hoboken). 2020; 72 Suppl 10:82-109.
PMID: 33091263
PMC: 8528225.
DOI: 10.1002/acr.24242.
Ritchlin C, Scher J
Curr Rheumatol Rep. 2019; 21(12):72.
PMID: 31813074
DOI: 10.1007/s11926-019-0876-z.
Strand V, Husni M, Betts K, Song Y, Singh R, Griffith J
BMC Rheumatol. 2019; 2:3.
PMID: 30886954
PMC: 6390550.
DOI: 10.1186/s41927-018-0011-1.
Kingsley G, Scott D
Psoriasis (Auckl). 2018; 5:71-81.
PMID: 29387584
PMC: 5683113.
DOI: 10.2147/PTT.S52893.
A discrete choice experiment to explore patients' willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis.
Rothery C, Bojke L, Richardson G, Bojke C, Moverley A, Coates L
Clin Rheumatol. 2016; 35(12):2967-2974.
PMID: 27796664
PMC: 5118397.
DOI: 10.1007/s10067-016-3452-1.
Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis.
Montepaone M, Lubrano E, Carboni A, Spadaro A
Open Access Rheumatol. 2014; 6:7-13.
PMID: 27790030
PMC: 5045109.
DOI: 10.2147/OARRR.S56048.
TWEAK-binding autoantibodies are generated during psoriatic arthritis and are not influenced by anti-TNF therapy.
Guis S, Berbis P, Stephan D, Bertin D, Amatore F, Balandraud N
J Transl Med. 2016; 14(1):185.
PMID: 27338143
PMC: 4917994.
DOI: 10.1186/s12967-016-0923-8.
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting.
Desai S, Frieden I, Gelfand J, High W, Kavanaugh A, Marghoob A
J Clin Aesthet Dermatol. 2015; 8(9 Suppl):S4-S26.
PMID: 26504503
PMC: 4591555.
Spondyloarthritis: Closing the gap in psoriatic arthritis.
Ritchlin C
Nat Rev Rheumatol. 2014; 10(12):704-5.
PMID: 25266455
DOI: 10.1038/nrrheum.2014.169.
Novel treatments with small molecules in psoriatic arthritis.
Hansen R, Kavanaugh A
Curr Rheumatol Rep. 2014; 16(9):443.
PMID: 25027606
DOI: 10.1007/s11926-014-0443-6.
Tailored approach to early psoriatic arthritis patients: clinical and ultrasonographic predictors for structural joint damage.
Miedany Y, El Gaafary M, Youssef S, Ahmed I, Nasr A
Clin Rheumatol. 2014; 34(2):307-13.
PMID: 24794490
DOI: 10.1007/s10067-014-2630-2.
Treatment algorithms for early psoriatic arthritis: do they depend on disease phenotype?.
Tillett W, McHugh N
Curr Rheumatol Rep. 2012; 14(4):334-42.
PMID: 22644331
DOI: 10.1007/s11926-012-0265-3.
[Psoriatric arthritis - a permanent challenge for rheumatologists and patients: part 2: imaging diagnostics, classification and therapy].
Finzel S, Englbrecht M
Z Rheumatol. 2011; 70(9):775-89.
PMID: 21979255
DOI: 10.1007/s00393-011-0870-y.
Management of psoriatic arthritis from the view of the dermatologist.
Chang C, Gottlieb A, Lizzul P
Nat Rev Rheumatol. 2011; 7(10):588-98.
PMID: 21912431
DOI: 10.1038/nrrheum.2011.125.
Cost effectiveness of golimumab for the treatment of active psoriatic arthritis.
Cummins E, Asseburg C, Prasad M, Buchanan J, Punekar Y
Eur J Health Econ. 2011; 13(6):801-9.
PMID: 21720868
DOI: 10.1007/s10198-011-0335-x.
Psoriatic arthritis: pharmacotherapy update.
Mease P
Curr Rheumatol Rep. 2010; 12(4):272-80.
PMID: 20490726
DOI: 10.1007/s11926-010-0108-z.
Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice.
Mumtaz A, FitzGerald O
Curr Rheumatol Rep. 2010; 12(4):264-71.
PMID: 20440659
DOI: 10.1007/s11926-010-0109-y.
[Treatment recommendations for psoriatic arthritis].
Boehncke W
Z Rheumatol. 2009; 68(10):842-4.
PMID: 19937037
DOI: 10.1007/s00393-009-0564-x.
Developments in the scientific and clinical understanding of the spondyloarthritides.
Sieper J
Arthritis Res Ther. 2009; 11(1):208.
PMID: 19232062
PMC: 2688219.
DOI: 10.1186/ar2562.